Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis ...( CAMBRIDGE Mass. and BERLIN /- Gen...),Health

CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) underway in Prague.

Charcot Award Lecture

Top-line, three-year data from a completed international, multi-center, Phase 2 clinical trial known as CAMMS223 that compared alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of multiple sclerosis will be presented on Sunday, Oct. 14 at 10 a.m. The data will be presented by Professor Alastair Compston during the prestigious Charcot Award lecture. The study results, taken at 36 months, compare alemtuzumab-treated patients with Rebif(R)-treated patients in the risk for sustained accumulation of disability and the risk for relapse. The data come from a pre-specified analysis conducted after three years of treatment for 334 patients in the study.

Details on two poster presentations

-- Alemtuzumab Improved Multiple Sclerosis Functional Composite Scores and

Delayed Time to First Relapse at 2-Year Interim Analysis Compared to

Subcutaneous Interferon Beta 1-a.

Sat. October 13 from 3:30-5:00 p.m. Alasdair J. Coles, M.D.

A further analysis of disability in CAMMS223, as measured by the Multiple Sclerosis Functional Composite Scale (MSFC), will be reported at ECTRIMS. Data from this scale, including quantitative tests on ambulation, manual dexterity, and cognition, will be presented along with new analyses of relapse events. These results build on the two-year analyses of the co-primary endpoints presented at the American Academy of Neurology annual meeting in May, 2007, which demonstrated that the risk of sustained accumulation of disability as well as the annualized relapse rate were m
'/>"/>